Drug-Coated versus Uncoated Balloon for Side Branch Protection in Coronary Bifurcation Lesions Treated with Provisional Stenting Using Drug-Eluting Stents: A Meta-analysis

Table 1

Characteristics of the included studies.

Study	Country	Design	Number of patients	Mean age (years)	Male (%)	Stents in main vessels	DCB in SB	UCB in SB	Follow-up duration	Outcomes reported
Herrador 2013	Spain	NRCT	100	62.5	83	DES (taxus liberté)	Sequent® please paclitaxel eluting balloon	Conventional UCB	12 months	SB stenosis, LLL, TLR, and MACE
Zong 2018	China	RCT	42	56.3	57.1	DES	Sequent® please paclitaxel eluting balloon	Conventional UCB	6 months	LLL, TLR and MACE
Zhang 2019	China	NRCT	60	60.1	71.7	DES	Sequent® please paclitaxel eluting balloon	Conventional UCB	9 months	LLL, TLR, and MACE
Jing 2020	China	RCT	222	60.8	72.5	DES	Bingo® paclitaxel eluting balloon	Conventional UCB	9 months	SB stenosis, LLL, TLR, and MACE
Li 2021	China	NRCT	219	63.4	80.8	DES (promus premier)	Sequent® please paclitaxel eluting balloon	Conventional UCB	12 months	LLL, TLR, and MACE
Bu 2021	China	RCT	60	60.3	73.3	DES	DCB	Conventional UCB	12 months	SB stenosis, TLR, and MACE
Zhang 2021	China	RCT	100	58.5	61	Everolimus eluting stents	Sequent® please paclitaxel eluting balloon	Conventional UCB	9 months	SB stenosis, LLL, TLR, and MACE

RCT, randomized controlled trial; NRCT, nonrandomized controlled trial; DES, drug-eluting stent; DCB, drug-coated balloon; UCB, uncoated balloon; SB, side branch; LLL, late lumen loss; TLR, target vessel revascularization; MACE, major adverse cardiovascular events.